• Multi-cancer hereditary syndrome testing: Genetic Counselors’ Perspectives. Weldon CB, Liang SY, Phillips KA, Douglas MP, Scheuner MT, Kurian AW, Schaa K, Roscow B, Erwin D, Trosman JR. American Society Clinical Oncology. June 4-8, 2021.
  • Financing of Germline Testing: Implications for Availability and Access. Lin GA, Scheuner MT, Trosman JR, Sales P, Ackerman S, Weldon CB, Kurian AW, Douglas MP, Phillips KA. American College of Medical Genetics. April 13-16, 2021.
  • Multi-Cancer Early Detection Screening Tests – “Liquid Biopsy Tests” - Are Here But Will Payers Provide Insurance Coverage? Phillips KA, Deverka PA. Precision Health and Integrated Diagnostics Center at Stanford. May 18, 2021.
  • Economic, Financial, and Policy Implications of Genetic Testing for Alzheimer's Disease and Related Dementias (ADRD). Douglas MP, Arias JJ, Lin GA, Tyler A, Jansen JP, Phillips KA. UCSF Dementia Day, May 18, 2021
  • Disease Modifying Treatments for Alzheimer’s Disease Are on The Horizon! How Can We Use Health Economic Models to Explore the Health Equity Impact and Cost-Effectiveness of Biomarkers for Early Detection? Jansen JP, Douglas MP, Phillips KA. UCSF Dementia Day, May 18, 2021.
  • Building the Evidence Base for Appropriate and Efficient Implementation of Emerging Genomic Tests for Disease Management and Screening. Phillips KA. Advances in Genome Biology and Technology. March 3, 2021.
  • Laboratory payment assistance programs decrease some disparities in access and affordability of hereditary cancer panel testing, but concerns still exist. Lin GA, Trosman JR, Douglas MP, Weldon CB, Scheuner MT, Kurian AW, Phillips KA. Breast Oncology Program. March 2, 2021.